Organization · Private Equity
BRESLIN AG and BRESLIN BIOTECH AG
Breslin AG and Breslin Biotech AG are private equity and corporate finance firms based in Switzerland, specializing in tailored transaction support and strategic advice in the life sciences and biotechnology sectors.
Overview
What BRESLIN AG and BRESLIN BIOTECH AG does
What BRESLIN AG and BRESLIN BIOTECH AG is
Breslin AG and Breslin Biotech AG are private equity and corporate finance firms based in Switzerland, specializing in tailored transaction support and strategic advice in the life sciences and biotechnology sectors.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 1996
- Approximate age
- About 30 years
- Structured capabilities
- Funder
- Last reviewed
- March 4, 2026
Official channels
Find BRESLIN AG and BRESLIN BIOTECH AG elsewhere
Open the official website or a supported primary organization account.
Capability profile
BRESLIN AG and BRESLIN BIOTECH AG as a funder
Investment thesis
Breslin invests in seed to early-stage ventures and academic and industrial spin-offs, aiming to drive technological innovation and market transformation through capital and strategic guidance.
Focus narrative
Breslin invests in seed to early-stage ventures and academic and industrial spin-offs. The firm aims to drive technological innovation and market transformation by providing capital and strategic guidance to emerging companies. Their investment activities are primarily concentrated in the life sciences and biotechnology sectors.
Focus and fit
- Stages
- Seed · Pre-seed · Growth Equity
- Regions
- Europe · Global · North America
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded notable exits
- Actelion, Anawa Laboratories, and GPC Biotech
Portfolio context
Current portfolio companies include CoBaLT GmbH, a medtech start-up in the financing phase; Memo Therapeutics, a spin-off from ETH Zurich with a follow-on financing of $14 million; and Qithera GmbH, a cancer start-up that closed financing in 2020. Notable exited companies include Actelion, which yielded a return of $53 million from a $3 million investment, and Anawa Laboratories, one of the first biotechs in Switzerland.
Common questions
What to know about BRESLIN AG and BRESLIN BIOTECH AG
Upseed classifies BRESLIN AG and BRESLIN BIOTECH AG under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.